Hualan Biotech (002007.SZ) announced semi-annual results, with net profit of 383 million yuan to mother, a year-on-year decrease of 25.69%

According to Zhitong Finance App, Hualan Biotech (002007.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,567 billion yuan, a year-on-year decrease of 12.88%; net profit attributable to shareholders of listed companies was 383 million yuan, a year-on-year decrease of 25.69%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 342 million yuan, a year-on-year decrease of 29.35%; and basic earnings per share were 0.21 yuan. The company plans to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders.

During the reporting period, based on the blood products business, the company consolidated its position in the blood products industry through measures such as increasing plasma collection, improving the overall utilization rate of plasma, optimizing the product structure, and increasing the production and development of products urgently needed in the market; integrating the company's R&D resources, concentrating superior resources to develop new vaccine products, doing a good job in the production and sale of products such as influenza virus lysis vaccines and freeze-dried human rabies vaccine (Vero cells), expanding and strengthening the vaccine business; carrying out R&D and production of innovative drugs and biosimilar drugs, adhering to innovation-driven development strategies to treat tumors and autoimmune diseases Drugs for major diseases of human life or health provide patients with safe, effective, and accessible drugs to protect human health; expand strategic cooperation with domestic and foreign superior companies, enhance the company's core competitiveness, and gradually form a large-scale biological industry pattern centered on blood products, vaccines, innovative drugs, and biosimilar drugs.